PFKFB4 facilitates palbociclib resistance in oestrogen receptor‐positive breast cancer by enhancing stemness

BACKGROUND: ER(+) breast cancer (ER(+) BC) is the most common subtype of BC. Recently, CDK4/6 inhibitors combined with aromatase inhibitors have been approved by FDA as the first‐line therapy for patients with ER(+) BC, and showed promising therapeutic efficacy in clinical treatment. However, resist...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Sijie, Bei, Yuncheng, Tian, Qiang, He, Jian, Wang, Rui, Wang, Qiuping, Sun, Luchen, Ke, Jiangqiong, Xie, Congying, Shen, Pingping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816941/
https://www.ncbi.nlm.nih.gov/pubmed/36127291
http://dx.doi.org/10.1111/cpr.13337

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816941/
https://www.ncbi.nlm.nih.gov/pubmed/36127291
http://dx.doi.org/10.1111/cpr.13337

Ejemplares similares